GlaxoSmithKline (GSK) Tops Q1 EPS by 18c

GlaxoSmithKline (NYSE: GSK) reported Q1 EPS of $1.20, $0.18 better than the analyst estimate of $1.02. Revenue for the quarter came in at $10.06 billion versus the consensus estimate of $9.48 billion.

For earnings history and earnings-related data on GlaxoSmithKline (GSK) click here.

You May Also Be Interested In

• Citi upgrades O-I Glass to Buy with $9 price target, opens 90-Day upside catalyst watch
• DZ Bank Starts SpaceX (SPCX) at Sell
• Wolfe Research on Lumentum (LITE): 'We continue to like the risk/reward in the shares'